Literature DB >> 33350491

A population-based study of concurrent prescriptions of opioid analgesic and selective serotonin reuptake inhibitor medications during pregnancy and risk for adverse birth outcomes.

Ayesha C Sujan1, Martin E Rickert1, Patrick D Quinn2, Christina Ludema3, Kelsey K Wiggs1, Henrik Larsson4,5, Paul Lichtenstein4, Catarina Almqvist4, Anna Sara Öberg4,6, Brian M D'Onofrio1,4.   

Abstract

BACKGROUND: Pregnant women with painful conditions often have mental health problems, including depression and anxiety. Co-morbid conditions may cause pregnant women to use multiple medications, although safety of such practice is poorly understood.
OBJECTIVES: We investigated the influence of combined prescriptions of opioid analgesics and selective serotonin reuptake inhibitors (SSRIs) during pregnancy on two adverse birth outcomes.
METHODS: We analysed Swedish population-based births (n = 688 914) between 2007 and 2013. Using national registers, we obtained data on filled medication prescriptions, birth outcomes, and a wide range of parental characteristics. We estimated preterm birth and small-for-gestational-age risk following independent or combined prescriptions of the two medications compared with no filled prescriptions for either medication. We adjusted for confounders using inverse probability of treatment weights.
RESULTS: After adjusting for confounders, preterm birth risk was higher among women with opioid analgesic prescriptions only (5.9%; risk ratio [RR] 1.27, 95% confidence interval [CI] 1.22, 1.33), SSRIs only (6.2%; RR 1.34, 95% CI 1.27, 1.42), and both medications (7.8%; RR 1.70, 95% CI 1.47, 1.96) compared with unexposed women (4.6%). The interaction between the medications on preterm birth was small (risk difference [RD] 0.4%, 95% CI -0.8%, 1.6%); relative excess risk due to interaction [RERI] 0.09, 95% CI -0.17, 0.34; RR 1.00, 95% CI 0.85, 1.17). For small for gestational age, risk was approximately 2% across all groups, and there was no interaction between the medications (RD 0.3%, 95% CI -0.4%, 1.1%); RERI 0.15, 95% CI -0.16, 0.47; RR 1.15, 95% CI 0.87, 1.52).
CONCLUSIONS: Compared with unexposed pregnancies, those with either medication alone had a small increased risk for preterm birth but no increased risk for small for gestational age. The magnitude of associations with combined exposure to both medications were not greater than the sum of the associations with each medication considered individually.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  antidepressant drugs; opioid analgesic; polypharmacy; prenatal care; preterm birth; small-for-gestational-age infant

Mesh:

Substances:

Year:  2020        PMID: 33350491      PMCID: PMC7878346          DOI: 10.1111/ppe.12721

Source DB:  PubMed          Journal:  Paediatr Perinat Epidemiol        ISSN: 0269-5022            Impact factor:   3.980


  43 in total

1.  Multiple imputation: current perspectives.

Authors:  Michael G Kenward; James Carpenter
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

2.  The impact of neighbourhood deprivation on adolescent violent criminality and substance misuse: a longitudinal, quasi-experimental study of the total Swedish population.

Authors:  Amir Sariaslan; Niklas Långström; Brian D'Onofrio; Johan Hallqvist; Johan Franck; Paul Lichtenstein
Journal:  Int J Epidemiol       Date:  2013-08       Impact factor: 7.196

3.  Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.

Authors:  Tove Abrahamsson; Jonas Berge; Agneta Öjehagen; Anders Håkansson
Journal:  Drug Alcohol Depend       Date:  2017-02-28       Impact factor: 4.492

4.  Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature.

Authors:  Mahsa M Yazdy; Rishi J Desai; Susan B Brogly
Journal:  J Pediatr Genet       Date:  2015-04-01

5.  Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006-2015.

Authors:  Jenna Wong; Aude Motulsky; Tewodros Eguale; David L Buckeridge; Michal Abrahamowicz; Robyn Tamblyn
Journal:  JAMA       Date:  2016 May 24-31       Impact factor: 56.272

6.  Accounting for Confounding in Observational Studies.

Authors:  Brian M D'Onofrio; Arvid Sjölander; Benjamin B Lahey; Paul Lichtenstein; A Sara Öberg
Journal:  Annu Rev Clin Psychol       Date:  2020-05-07       Impact factor: 18.561

7.  A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.

Authors:  Hsiang Huang; Shane Coleman; Jeffrey A Bridge; Kimberly Yonkers; Wayne Katon
Journal:  Gen Hosp Psychiatry       Date:  2013-10-02       Impact factor: 3.238

8.  Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden.

Authors:  Karin C Söderberg; Lucie Laflamme; Jette Möller
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

9.  Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.

Authors:  Karol Kaltenbach; Amber M Holbrook; Mara G Coyle; Sarah H Heil; Amy L Salisbury; Susan M Stine; Peter R Martin; Hendrée E Jones
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

10.  Tramadol: seizures, serotonin syndrome, and coadministered antidepressants.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2009-04
View more
  2 in total

1.  Pregnant Women Following Bariatric Surgery: a Focus on Maternal Mental Health and Its Impact on Birth Outcomes.

Authors:  Yang Yu; Qianheng Ma; Stefanie Hollenbach; Yuansheng Zhu; Susan Groth
Journal:  Obes Surg       Date:  2022-09-22       Impact factor: 3.479

2.  Prenatal Exposure to Mercury, Manganese, and Lead and Adverse Birth Outcomes in Suriname: A Population-Based Birth Cohort Study.

Authors:  Vinoj H Sewberath Misser; Ashna D Hindori-Mohangoo; Arti Shankar; Jeffrey K Wickliffe; Maureen Y Lichtveld; Dennis R A Mans
Journal:  Toxics       Date:  2022-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.